Associated Papers
A mitochondrial amidoxime-reducing component 1 (mARC1) A168T amino acid substitution does not confer protection from MASH and fibrosis in multiple mouse models of chronic liver disease.
Pandovski S et al.
The Biochemical Journal, 2026
Loss of mitochondrial amidoxime-reducing component 1 (mARC1) prevents disease progression by reducing fibrosis in multiple mouse models of chronic liver disease.
Coyne ES et al.
Hepatology Communications, 2025
mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes.
Jones AK et al.
Hepatology Communications, 2024
Fatty liver disease protective MTARC1 p.A165T variant reduces the protein stability of MTARC1.
Wu M et al.
Biochemical and Biophysical Research Communications, 2024
Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse.
Smagris E et al.
Plos Genetics, 2024
Hepatocyte mARC1 promotes fatty liver disease.
Lewis LC et al.
Jhep Reports : Innovation in Hepatology, 2023
A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease.
Emdin CA et al.
Plos Genetics, 2020
Functional characterization of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy Caucasians.
Ott G et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2014
Select a paper to view details